Federal Register / Vol. 76, No. 58 / Friday, March 25, 2011 / Notices 16797 

steering committees and working groups 

to ensure appropriate project 

implementation, oversight, and 

management for all projects under the 

PPP. 

• Development of a scientific review 

panel to evaluate the progress of 

projects funded under the PPP and 

development of feasibility plans for 

additional projects aligned with PASI. 

• Coordination with FDA and other 

partners; the development and 

publication of scientific articles in 

support of educational and outreach 

activities (with data, know-how, and 

other outcomes from the 

aforementioned projects supported 

under the PPP) and to benefit patients 

and other stakeholders. 

• Development of a strategy to 

identify and establish relationships with 

key experts in the fields of anesthesia 

and sedation, including stakeholders 

from industry, professional 

organizations, academia, and awardees 

of the projects under the ‘‘research and 

analysis’’ section for leveraging and 

collaborative efforts under PASI. 

• Coordination of annual scientific 

workshops with collaboration by FDA 

and the aforementioned experts in the 

fields of anesthesia and sedation, 

including stakeholders from industry, 

professional organizations, academia, 

and Government Agencies. 

2. Research projects (which may 

include, but are not limited to): 

• Clinical trials including 

prospective, randomized, and blinded 

investigations assessing the immediate 

and delayed neurodevelopmental effects 

of regional/caudal anesthesia versus 

general anesthesia in neonates/infants; 

• Observational trials including the 

comparison of two groups of children, 

one group exposed to general anesthesia 

within the first 3 years of life and the 

other, unexposed. Assessments should 

utilize neuropsychological tests of 

attention, memory, motor function, and 

behavior; and 

• Epidemiologic investigations 

surveying large existing population 

databases for cognitive developmental 

effects where exposure to general 

anesthesia before the age of 3 can be 

compared to the overall population. 

C. Eligibility Information 

Higher education institutions: 

• Public/state-controlled institutions 

of higher education 

• Private institutions of higher 

education 

The following types of higher 

education institutions are always 

encouraged to apply for National 

Institutes of Health support as public or 

private institutions of higher education: 

• Hispanic serving institutions 

• Historically Black colleges and 

universities 

• Tribally controlled colleges and 

universities 

• Alaska Native and Native Hawaiian 

serving institutions 

Nonprofits other than institutions of 

higher education 

• Nonprofits with 501(c)(3) Internal 

Revenue Service (IRS) status (other than 

institutions of higher education) 

• Nonprofits without 501(c)(3) IRS 

status (other than institutions of higher 

education) 

For-profit organizations: 

• Small businesses 

• For-profit organizations (other than 

small businesses) 

Other: 

• Regional organizations 

Non-domestic (non-U.S.) entities 

(foreign organizations) are not eligible to 

apply. Foreign (non-U.S.) components 

of U.S. organizations are not allowed. 

II. Award Information/Funds Available 

A. Award Amount 

FDA intends to fund one or more 

awards, corresponding to a total of $1 

million, for fiscal year 2011, to carry out 

the project management and research 

project objectives described in Part I of 

this document. Future year amounts 

will depend on annual appropriations. 

No more than four awards are 

anticipated under this FOA. The 

number of awards is contingent upon 

FDA appropriations and the submission 

of a sufficient number of meritorious 

applications. 

B. Length of Support 

The anticipated length of the 

individual awards is 5 years. 

III. Electronic Application, 

Registration, and Submission 

Only electronic applications will be 

accepted. To submit an electronic 

application in response to this FOA, 

applicants should first review the full 

announcement located at http:// 

grants.nih.gov/grants/guide/ (select the 

‘‘Request for Applications’’ link), 

http://www.grants.gov/ (see ‘‘For 

Applicants’’ section) and http:// 

www.fda.gov/AboutFDA/ 

PartnershipsCollaborations/ 

PublicPrivatePartnershipProgram/ 

ucm166082.htm. (FDA has verified the 

Web site addresses throughout this 

document, but FDA is not responsible 

for any subsequent changes to the Web 

sites after this document publishes in 

the Federal Register.) For all 

electronically submitted applications, 

the following steps are required: 

• Step 1: Obtain a Dun and Bradstreet 

(DUNS) Number 

• Step 2: Register With Central 

Contractor Registration 

• Step 3: Obtain Username and 

Password 

• Step 4: Authorized Organization 

Representative (AOR) Authorization 

• Step 5: Track AOR Status 

• Step 6: Register With Electronic 

Research Administration (eRA) 

Commons Steps 1 through 5, in detail, 

can be found at http:// 

www07.grants.gov/applicants/ 

organization_registration.jsp. Step 6, in 

detail, can be found at https:// 

commons.era.nih.gov/commons/ 

registration/registrationInstructions.jsp. 

After you have followed these steps, 

submit electronic applications to: 

http://www.grants.gov/. 

Dated: March 21, 2011. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2011–7055 Filed 3–24–11; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Research 

Resources; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Research Resources Special Emphasis Panel; 

LOAN REPAYMENT. 

Date: April 7, 2011. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Carol Lambert, PhD, 

Scientific Review Officer, Office of Review, 

NCRR, National Institutes of Health, 6701 

Democracy Blvd., One Democracy Plaza, 

Room 1076, MSC 4874, Bethesda, MD 20892– 

4874, 301–435–0814, lambert@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 


erowe on DSK5CLS3C1PROD with NOTICES
16798 Federal Register / Vol. 76, No. 58 / Friday, March 25, 2011 / Notices 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research; 93.371, Biomedical 

Technology; 93.389, Research Infrastructure, 

93.306, 93.333; 93.702, ARRA Related 

Construction Awards., National Institutes of 

Health, HHS) 

Dated: March 21, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–7137 Filed 3–24–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Host Response to 

Francisella. 

Date: May 11, 2011. 

Time: 1 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, Bethesda, MD 20817, 

(Telephone Conference Call) 

Contact Person: Lynn Rust, PhD, Scientific 

Review Officer,Scientific Review Program, 

Division of Extramural Activities, NIAID/ 

NIH/DHHS, 6700B Rockledge Drive, MSC 

7616, Bethesda, MD 20892, (301) 402–3938, 

lr228v@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: March 21, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–7136 Filed 3–24–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 USC, 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Initial 

Review Group; Neuroscience Review 

Subcommittee. 

Date: June 9–10, 2011. 

Time: 8:30 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20852. 

Contact Person: Beata Buzas, PhD, 

Scientific Review Officer, National Institute 

on Alcohol Abuse and Alcoholism, National 

Institutes of Health, 5635 Fishers Lane, Room 

2081, Rockville, MD 20852, 301–443–0800, 

bbuzas@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards., National 

Institutes of Health, HHS) 

Dated: March 18, 2011. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–7134 Filed 3–24–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Mechanisms 

of Neurodegeneration. 

Date: April 18, 2011. 

Time: 11 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Toby Behar, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4136, 

MSC 7850, Bethesda, MD 20892, (301) 435– 

4433, behart@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: March 21, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–7133 Filed 3–24–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Internal Agency Docket No. FEMA–1955– 

DR; Docket ID FEMA–2011–0001] 

Utah; Amendment No. 1 to Notice of a 

Major Disaster Declaration 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice. 

SUMMARY: This notice amends the notice 

of a major disaster declaration for the 

State of Utah (FEMA–1955–DR), dated 

February 11, 2011, and related 

determinations. 

DATES: Effective Date: March 11, 2011. 

FOR FURTHER INFORMATION CONTACT: 

Peggy Miller, Office of Response and 

Recovery, Federal Emergency 


erowe on DSK5CLS3C1PROD with NOTICES